NCT00381342 - Safety and Efficacy of Exenatide as Monotherapy | Biotech Hunter

Enrollment

233

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

exenatide

Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day

DRUG

exenatide

Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day, then exenatide subcutaneous injection, 10 mcg twice a day

DRUG

placebo

subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day

Trial Locations (19)

Unknown

Research Site, Idaho Falls

Research Site, Indianapolis

Research Site, Aligarh

Research Site, Bangalore

Research Site, Chennai

Research Site, Indore

Research Site, Karnāl

Research Site, New Delhi

Research Site, Vellore

Research Site, Manatí

Research Site, San Juan

Research Site, Alba Iulia

Research Site, Baia Mare

Research Site, Bucharest

Research Site, Galati

Research Site, Oradea

Research Site, Târgu Mureş

Research Site, Moscow

Research Site, Saint Petersburg